Metastatic melanoma patients’ sensitivity to ipilimumab cannot be predicted by tumor characteristics

Immune checkpoint inhibitors have dramatically changed the prognosis for patients with metastatic melanoma. However, not all patients respond to therapy and toxicities can be severe leaving need for reliable clinical predictive markers. METHODS: We examined primary tumor characteristics including ul...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossfeld, Kara, Hade, Erinn M., Gangi, Alexandra, Perez, Matthew, Kinsey, Emily N., Grabska, Joanna, Ederle, Ashley, Zager, Jonathan, Salama, April K., Olencki, Thomas E, Beasley, Georgia M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673131/
https://www.ncbi.nlm.nih.gov/pubmed/29177235
http://dx.doi.org/10.1097/IJ9.0000000000000043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5673131/
https://www.ncbi.nlm.nih.gov/pubmed/29177235
http://dx.doi.org/10.1097/IJ9.0000000000000043

Ejemplares similares